Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 2/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34473806 | 0.79 | KLK7 (0.36) | ELANEKDM4EMAPTTHRBNR1H2 | |
| SCHEMBL31750269 | 0.79 | KLK7 (0.36) | ELANEKDM4EMAPTTHRBNR1H2 | |
| SCHEMBL1420420 | 0.75 | DPP4 (0.32) | GPR119KDM4EMAPTTHRBNR1H2 | |
| SCHEMBL1847232 | 0.73 | KDM4E (0.32) | GPR119KDM4EMAPTTHRBNR1H2 | |
| SCHEMBL2196268 | 0.73 | CHRM2 (0.41) | GPR119PREPELANEKDM4EMAPT | |
| SCHEMBL2196261 | 0.73 | CHRM2 (0.41) | GPR119PREPELANEKDM4EMAPT | |
| SCHEMBL27635233 | 0.68 | MAPK1 (0.43) | ELANEKDM4EMAPTTHRBCHRM2 | |
| SCHEMBL18593027 | 0.68 | MAPK1 (0.43) | ELANEKDM4EMAPTTHRBCHRM2 | |
| SCHEMBL3733352 | 0.67 | CHRM2 (0.41) | GPR119PREPELANEKDM4EMAPT | |
| SCHEMBL3733204 | 0.67 | CHRM2 (0.41) | GPR119PREPELANEKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | GPR119 47/4885PREP 3703/4885ELANE 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.